BioCentury

7:00 AM GMT, Jul 26, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

Savara: Deep Focus on Lungs

The objective of most inhalation delivery technologies is to deliver therapeutic directly to the target organ while avoiding systemic issues. Savara Inc. believes its nanocluster dry powder inhalation technology will allow the biotech to deliver more active drug to the deep lung, which the company believes will translate into more efficient delivery and new indications for inhaled therapeutics.

According to CEO Robert Neville, current dry powder delivery technologies rely on bulky carrier molecules like lactose,

Read the full 742 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.